Cited by 134Parkinson's Disease Mechanisms and TreatmentsNerve injury and regenerationNuclear Receptors and Signaling

The DOI matches its Crossref record; 59 of the 60 references it cites were found in a registry or an index.

Effects of Brain-derived Neurotrophic Factor on 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in Monkeys

Tsukahara, Tetsuya, Takeda, Makoto, Shimohama, Shun, Ohara, Osamu, Hashimoto, Nobuo·1995·Neurosurgery

DOI 10.1227/00006123-199510000-00018

Open this paper in CoChat — free account

Abstract

The effects of intrathecal infusion of brain-derived neurotrophic factor (BDNF) were examined in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonian model in monkeys. Nine Japanese monkeys were divided randomly into three groups, an untreated control (n = 3), a BDNF group (n = 3), and a non-BDNF group (n = 3). Animals in the BDNF group received continuous intrathecal infusion of 10 ml of cell culture medium containing 10 micrograms of BDNF protein; the non-BDNF group received intrathecal infusion of the same culture medium without BDNF. To induce parkinsonian syndromes, a total of 1 mg/kg 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine was administered intravenously to each monkey in both the BDNF and non-BDNF groups. The neurological signs in the monkeys were monitored for 2 weeks and were scored according to the monkey parkinsonism rating scale; histological changes in the substantia nigra were evaluated after the 2-week observation period. The BDNF-treated animals remained asymptomatic during the 1st week and showed mild parkinsonism during the 2nd week, whereas the non-BDNF group showed typical parkinsonian syndrome during the 1st week, with deterioration in the 2nd week. Histological damage in the substantia nigra correlated well with the clinical features. Severe neuronal cell loss in the substantia nigra was observed in animals with severe parkinsonism (those in the non-BDNF group), whereas significantly less damage was observed in this region in the BDNF group.(ABSTRACT TRUNCATED AT 250 WORDS)

Integrity signals

Registry

Crossref · 10.1227/00006123-199510000-00018

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Burns, R. S., Chiueh, C. C., Markey, S. P., Ebert, M. H., Jacobowitz, D. M., & Kopin, I. J. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.14.4546 · Cited by 2,149
Purification of a new neurotrophic factor from mammalian brain.
Barde, Y. A., Edgar, D., & Thoenen, H. (1982) · The EMBO Journal · doi:10.1002/j.1460-2075.1982.tb01207.x · Cited by 1,822
BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra
Hyman, C., Hofer, M., Barde, Y., Juhasz, M., Yancopoulos, G. D., Squinto, S. P., & Lindsay, R. M. (1991) · Nature · doi:10.1038/350230a0 · Cited by 1,503
The trk Proto-Oncogene Product: a Signal Transducing Receptor for Nerve Growth Factor
Kaplan, D. R., Hempstead, B. L., Martin-Zanca, D., Chao, M. V., & Parada, L. F. (1991) · Science · doi:10.1126/science.1850549 · Cited by 1,379
Chronic parkinsonism secondary to intravenous injection of meperidine analogues
Davis, G. C., Williams, A. C., Markey, S. P., Ebert, M. H., Caine, E. D., Reichert, C. M., & Kopin, I. J. (1979) · Psychiatry Research · doi:10.1016/0165-1781(79)90006-4 · Cited by 1,377
Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine
Nicklas, W. J., Vyas, I. L., & Heikkila, R. E. (1985) · Life Sciences · doi:10.1016/0024-3205(85)90146-8 · Cited by 1,273
Identification and characterization of a novel member of the nerve growth factor/brain-derived neurotrophic factor family
Hohn, A., Leibrock, J., Bailey, K., & Barde, Y.-A. (1990) · Nature · doi:10.1038/344339a0 · Cited by 1,145
Tyrosine phosphorylation and tyrosine kinase activity of the trk proto-oncogene product induced by NGF
Kaplan, D. R., Martı́n-Zanca, D., & Parada, L. F. (1991) · Nature · doi:10.1038/350158a0 · Cited by 1,059
Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey
Langston, J. W., Forno, L. S., Rebert, C. S., & Irwin, I. (1984) · Brain Research · doi:10.1016/0006-8993(84)90777-7 · Cited by 922

Show all 60 references

Research works printed but not linked: 1

Burns, 1983, A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Proc Natl Acad Sci U S A, 80, 4546, 10.1073/pnas.80.14.4546 · DOI

Sorted by citations

Brain-derived neurotrophic factor in neurodegenerative diseases
Zuccato, C., & Cattaneo, E. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.54 · Cited by 947
Brain-derived neurotrophic factor in the control human brain, and in Alzheimer’s disease and Parkinson’s disease
Murer, M. G., Yan, Q., & Raisman-Vozari, R. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00014-9 · Cited by 874
Potential therapeutic uses of BDNF in neurological and psychiatric disorders
Nagahara, A. H., & Tuszynski, M. H. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3366 · Cited by 867
The role of neuronal growth factors in neurodegenerative disorders of the human brain
Connor, B. J., & Dragunow, M. (1998) · Brain Research Reviews · doi:10.1016/s0165-0173(98)00004-6 · Cited by 538
Reduced BDNF mRNA Expression in the Parkinson's Disease Substantia Nigra
Howells, D. W., Porritt, M. J., Wong, J. Y. F., Batchelor, P. E., Kalnins, R., Hughes, A. J., & Donnan, G. A. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7483 · Cited by 513
BDNF as a Promising Therapeutic Agent in Parkinson’s Disease
Palasz, E., Wysocka, A., Gasiorowska, A., Chalimoniuk, M., Niewiadomski, W., & Niewiadomska, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031170 · Cited by 504
Animal models of Parkinson's disease: An empirical comparison with the phenomenology of the disease in man
Gerlach, M., & Riederer, P. F. (1996) · Journal of Neural Transmission · doi:10.1007/bf01291788 · Cited by 496
Caloric restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson's disease
Maswood, N., Young, J., Tilmont, E. M., Zhang, Z., Gash, D. M., Gerhardt, G. A., Grondin, R., Roth, G. S., Mattison, J. A., Lane, M. A., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405831102 · Cited by 383
The MPTP model of Parkinson's disease
Smeyne, R. J., & Jackson-Lewis, V. R. (2004) · Molecular Brain Research · doi:10.1016/j.molbrainres.2004.09.017 · Cited by 387
Emerging therapies in Parkinson disease — repurposed drugs and new approaches
Elkouzi, A., Vedam‐Mai, V., Eisinger, R. S., & Okun, M. S. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0155-7 · Cited by 316
Intraventricular Brain-Derived Neurotrophic Factor Reduces Infarct Size after Focal Cerebral Ischemia in Rats
Schäbitz, W.-R., Schwab, S., Spranger, M., & Hacke, W. (1997) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199705000-00003 · Cited by 322
Tyrosine Hydroxylase and Parkinson’s Disease
Haavik, J., & Toska, K. (1998) · Molecular Neurobiology · doi:10.1007/bf02741387 · Cited by 263
Environmental enrichment in adulthood eliminates neuronal death in experimental Parkinsonism
Faherty, C. J., Shepherd, K. R., Herasimtschuk, A., & Smeyne, R. J. (2004) · Molecular Brain Research · doi:10.1016/j.molbrainres.2004.08.008 · Cited by 241
Cellular, molecular, and clinical mechanisms of action of deep brain stimulation—a systematic review on established indications and outlook on future developments
Jakobs, M., Fomenko, A., Lozano, A. M., & Kiening, K. L. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201809575 · Cited by 232
Brain‐derived neurotrophic factor mediates an excitoprotective effect of dietary restriction in mice
Duan, W., Guo, Z., & Mattson, M. P. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00071.x · Cited by 185
Dietary Restriction Stimulates BDNF Production in the Brain and Thereby Protects Neurons Against Excitotoxic Injury
Duan, W., Lee, J., Guo, Z., & Mattson, M. P. (2001) · Journal of Molecular Neuroscience · doi:10.1385/jmn:16:1:1 · Cited by 183
Gene Therapy for Parkinson’s Disease, An Update
Axelsen, T. M., & Woldbye, D. P. D. (2018) · Journal of Parkinson s Disease · doi:10.3233/jpd-181331 · Cited by 185
BDNF and the diseased nervous system: a delicate balance between adaptive and pathological processes of gene regulation
Hu, Y., & Russek, S. J. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05237.x · Cited by 164
Brain-derived neurotrophic factor
Benarroch, E. E. (2015) · Neurology · doi:10.1212/wnl.0000000000001507 · Cited by 138
Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons
Porritt, M. J., Batchelor, P. E., & Howells, D. W. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2004.11.030 · Cited by 135
Brain-derived neurotrophic factor as a drug target for CNS disorders
Pezet, S., & Malcangio, M. (2004) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.8.5.391 · Cited by 132
Brain Derived Neurotrophic Factor: A novel neurotrophin involved in psychiatric and neurological disorders
Balaratnasingam, S., & Janča, A. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.01.006 · Cited by 133
The Role of Astrocytes in the Neurorepair Process
Chiareli, R. A., Carvalho, G. A., Marques, B. L., Mota, L. S., Oliveira‐Lima, O. C., Gomes, R. M., Birbrair, A., Gomez, R. S., Simão, F., Klempin, F., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.665795 · Cited by 130
Estrogen and SERM neuroprotection in animal models of Parkinson's disease
Morissette, M., Al-Sweidi, S., Callier, S., & Paolo, T. D. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.04.008 · Cited by 125
The Mechanisms by Which the Ketone Body D-β-Hydroxybutyrate May Improve the Multiple Cellular Pathologies of Parkinson's Disease
Norwitz, N. G., Hu, M. T., & Clarke, K. (2019) · Frontiers in Nutrition · doi:10.3389/fnut.2019.00063 · Cited by 110
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level
Kupsch, A. R., Sautter, J., Schwarz, J., Riederer, P. F., Gerlach, M., & Oertel, W. H. (1996) · Brain Research · doi:10.1016/s0006-8993(96)00917-1 · Cited by 110
Functional interactions between somatodendritic dopamine release, glutamate receptors and brain-derived neurotrophic factor expression in mesencephalic structures of the brain
Bustos, G. A., Abarca, J., Campusano, J. M., Bustos, V., Noriega, V., & Aliaga, E. (2004) · Brain Research Reviews · doi:10.1016/j.brainresrev.2004.05.002 · Cited by 96
Ultrasound-responsive neurotrophic factor-loaded microbubble- liposome complex: Preclinical investigation for Parkinson's disease treatment
Lin, C., Lin, Y.-C., Huang, C.-Y., Wu, S.-R., Chen, C., & Liu, H.-L. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.02.044 · Cited by 94
Panax ginseng is neuroprotective in a novel progressive model of Parkinson's disease
Kampen, J. M. V., Baranowski, D. C., Shaw, C. A., & Kay, D. G. (2013) · Experimental Gerontology · doi:10.1016/j.exger.2013.11.012 · Cited by 91
Therapeutic Potential of Neurotrophic Factors in Neurodegenerative Diseases
Levy, Y. S., Gilgun‐Sherki, Y., Melamed, E., & Offen, D. (2005) · BioDrugs · doi:10.2165/00063030-200519020-00003 · Cited by 92
Serum level of brain-derived neurotrophic factor in Parkinson's disease: a meta-analysis
Jiang, L., Zhang, H., Wang, C., Ming, F., Shi, X., & Yang, M. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.07.010 · Cited by 88
Secretion of brain‐derived neurotrophic factor from brain microvascular endothelial cells
Wang, H., Ward, N., Boswell, M., & Katz, D. M. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.04682.x · Cited by 81
Role of BDNF in Central Motor Structures and Motor Diseases
He, Y., Zhang, X., Yung, W., Zhu, J., & Wang, J. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8466-y · Cited by 84
Chronic deprivation of TrkB signaling leads to selective late-onset nigrostriatal dopaminergic degeneration
Baydyuk, M., Nguyen, M. T., & Xu, B. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.12.018 · Cited by 80
Neurotrophin Signaling and Stem Cells—Implications for Neurodegenerative Diseases and Stem Cell Therapy
Pramanik, S., Sulistio, Y. A., & Heese, K. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0214-7 · Cited by 77
Orexin-A Exerts Neuroprotective Effects via OX1R in Parkinson’s Disease
Liu, M., Xue, Y., Liu, C., Liu, Y.-H., Diao, H., Wang, Y., Pan, Y.-P., & Chen, L. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00835 · Cited by 72
Pgc-1α Overexpression Downregulates Pitx3 and Increases Susceptibility to MPTP Toxicity Associated with Decreased Bdnf
Clark, J., Silvaggi, J. M., Kiselak, T., Zheng, K., Clore, E. L., Dai, Y., Bass, C. E., & Simon, D. K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048925 · Cited by 70
Intracerebroventricular 4-Methylcatechol (4-MC) Ameliorates Chronic Pain Associated with Depression-Like Behavior via Induction of Brain-Derived Neurotrophic Factor (BDNF)
Fukuhara, K., Ishikawa, K., Yasuda, S., Kishishita, Y., Kim, H.-K., Kakeda, T., Yamamoto, M., Norii, T., & Ishikawa, T. (2011) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-011-9782-2 · Cited by 72
Transforming growth factor‐β1 enhances expression of brain‐derived neurotrophic factor and its receptor, TrkB, in neurons cultured from rat cerebral cortex
Sometani, A., Kataoka, H., Nitta, A., Fukumitsu, H., Nomoto, H., & Furukawa, S. (2001) · Journal of Neuroscience Research · doi:10.1002/jnr.1229 · Cited by 69
Bispecific antibody shuttles targeting CD98hc mediate efficient and long-lived brain delivery of IgGs
Pornnoppadol, G., Bond, L. G., Lucas, M. J., Zupancic, J. M., Kuo, Y., Zhang, B., Greineder, C. F., & Tessier, P. M. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.09.008 · Cited by 75
Engineered BDNF producing cells as a potential treatment for neurologic disease
Deng, P., Anderson, J. D., Yu, A. S., Annett, G., Fink, K. D., & Nolta, J. A. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1183641 · Cited by 70
Differential effects of GDNF and BDNF on cultured ventral mesencephalic neurons
Feng, L., Wang, C.-Y., Jiang, H., Oho, C., Mizuno, K., Dugich‐Djordjevic, M. M., & Lu, B. (1999) · Molecular Brain Research · doi:10.1016/s0169-328x(99)00015-7 · Cited by 66
Neurotrophic factors for disease-modifying treatments of Parkinson's disease: gaps between basic science and clinical studies
Chmielarz, P., & Saarma, M. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00120-3 · Cited by 69
Potential Therapeutic Effects of Neurotrophins for Acute and Chronic Neurological Diseases
Cai, J., Hua, F., Yuan, L., Tang, W., Lu, J., Yu, S., Wang, X., & Hu, Y. (2014) · BioMed Research International · doi:10.1155/2014/601084 · Cited by 66
7,8‐dihydroxyflavone Ameliorates Motor Deficits Via Suppressing α ‐synuclein Expression and Oxidative Stress in the MPTP ‐induced Mouse Model of Parkinson's Disease
Li, X., Dai, C., Chen, L., Zhou, W., Han, H., & Dong, Z. (2016) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12555 · Cited by 67
Secretion of brain‐derived neurotrophic factor from PC12 cells in response to oxidative stress requires autocrine dopamine signaling
Wang, H., Yuan, G., Prabhakar, N. R., Boswell, M. V., & Katz, D. M. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03572.x · Cited by 66
Attenuation of MPTP neurotoxicity by rolipram, a specific inhibitor of phosphodiesterase IV
Yang, L., Calingasan, N. Y., Lorenzo, B. J., & Beal, M. F. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.02.010 · Cited by 65
The effects of motor rehabilitation training on clinical symptoms and serum BDNF levels in Parkinson’s disease subjects
Angelucci, F., Piermaria, J., Gelfo, F., Shofany, J., Tramontano, M., Fiore, M., Caltagirone, C., & Peppe, A. (2016) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2015-0322 · Cited by 65
Focused ultrasound enhanced intranasal delivery of brain derived neurotrophic factor produces neurorestorative effects in a Parkinson’s disease mouse model
Ji, R., Smith, M., Niimi, Y., Karakatsani, M. E., Murillo, M. F., Jackson-Lewis, V. R., Przedborski, S., & Konofagou, E. E. (2019) · Scientific Reports · doi:10.1038/s41598-019-55294-5 · Cited by 67
The Role of Brain-Derived Neurotrophic Factor Signaling in Central Nervous System Disease Pathogenesis
Dou, S.-H., Cui, Y., Huang, S.-M., & Zhang, B. (2022) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2022.924155 · Cited by 67
CART peptide promotes the survival of hippocampal neurons by upregulating brain-derived neurotrophic factor
Wu, B., Hu, S., Yang, M. H., Pan, H., & Zhu, S. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.06.117 · Cited by 63
Striatal dopamine transporter binding correlates with serum BDNF levels in patients with striatal dopaminergic neurodegeneration
Ziebell, M., Khalid, U., Klein, A. B., Aznar, S., Thomsen, G., Jensen, P., & Knudsen, G. M. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.11.010 · Cited by 62
D-Ala2-GIP-glu-PAL is neuroprotective in a chronic Parkinson's disease mouse model and increases BNDF expression while reducing neuroinflammation and lipid peroxidation
Li, Y., Liu, W., Li, L., & Hölscher, C. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.11.050 · Cited by 62
Glia cell number modulates sensitivity to MPTP in mice
Smeyne, M., Jiao, Y., Shepherd, K. R., & Smeyne, R. J. (2005) · Glia · doi:10.1002/glia.20233 · Cited by 61
Dopamine D1–D2 Receptor Heteromer in Dual Phenotype GABA/Glutamate-Coexpressing Striatal Medium Spiny Neurons: Regulation of BDNF, GAD67 and VGLUT1/2
Perreault, M. L., Fan, T., Alijaniaram, M., O’Dowd, B. F., & George, S. R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033348 · Cited by 60
Cytoprotective effects of growth factors: BDNF more potent than GDNF in an organotypic culture model of Parkinson's disease
Stahl, K., Mylonakou, M. N., Skare, Ø., Amiry-Moghaddam, M. R., & Torp, R. (2011) · Brain Research · doi:10.1016/j.brainres.2010.12.090 · Cited by 63
Pharmacologically active microcarriers delivering BDNF within a hydrogel: Novel strategy for human bone marrow-derived stem cells neural/neuronal differentiation guidance and therapeutic secretome enhancement
Kandalam, S., Sindji, L., Delcroix, G. J.-R., Violet, F., Garric, X., André, E. M., Schiller, P. C., Venier‐Julienne, M., Rieux, A. D., Guicheux, J., et al. (2016) · Acta Biomaterialia · doi:10.1016/j.actbio.2016.11.030 · Cited by 64
Omega-3 Deficiency and Neurodegeneration in the Substantia Nigra: Involvement of Increased Nitric Oxide Production and Reduced BDNF Expression
Cardoso, H. D., Santos Junior, E. F. D., de Santana, D. F., Gonçalves-Pimentel, C., Angelim, M. K., Isaac, A. R., Lagranha, C. J., Guedes, R. C. A., Beltrão, E. I., Morya, E., et al. (2014) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.12.023 · Cited by 55
Exercise does not protect against MPTP-induced neurotoxicity in BDNF happloinsufficent mice
Gerecke, K. M., Jiao, Y., Pagala, V., & Smeyne, R. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043250 · Cited by 53
Neurotrophic factors hold promise for the future of Parkinson’s disease treatment: is there a light at the end of the tunnel?
Nasrolahi, A., Mahmoudi, J., Akbarzadeh, A., Karimipour, M., Sadigh‐Eteghad, S., Salehi, R., & Farhoudi, M. (2018) · Reviews in the Neurosciences · doi:10.1515/revneuro-2017-0040 · Cited by 52
Synucleinopathy-associated pathogenesis in Parkinson’s disease and the potential for brain-derived neurotrophic factor
Miller, K. M., Mercado, N. M., & Sortwell, C. E. (2021) · npj Parkinson s Disease · doi:10.1038/s41531-021-00179-6 · Cited by 54
Brain-derived neurotrophic factor (BDNF) Val66Met polymorphisms in Parkinson's disease and age of onset
Hong, C., Liu, H.-C., Liu, T., Lin, C., Cheng, C., & Tsai, S. (2003) · Neuroscience Letters · doi:10.1016/j.neulet.2003.09.009 · Cited by 50
Gene Therapy for Neurological Disorders: Challenges and Future Prospects for the Use of Growth Factors for the Treatment of Parkinsons Disease
Manfredsson, F. P., Okun, M. S., & Mandel, R. J. (2009) · Current Gene Therapy · doi:10.2174/156652309789753400 · Cited by 46
Serum concentration and clinical significance of brain-derived neurotrophic factor in patients with Parkinson’s disease or essential tremor
Huang, Y., Yun, W., Zhang, M., Luo, W., & Zhou, X. (2018) · Journal of International Medical Research · doi:10.1177/0300060517748843 · Cited by 46
Intranasal gene delivery for treating Parkinson’s disease: overcoming the blood–brain barrier
Aly, A. E.-E., & Waszczak, B. L. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2015.1069815 · Cited by 46
The development of encapsulated cell technologies as therapies for neurological and sensory diseases
Zanin, M., Pettingill, L. N., Harvey, A. R., Emerich, D., Thanos, C. G., & Shepherd, R. K. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.021 · Cited by 46
4-Methylcatechol Increases Brain-Derived Neurotrophic Factor Content and mRNA Expression in Cultured Brain Cells and in Rat Brain In Vivo
Nitta, A., Ito, M., Fukumitsu, H., Ohmiya, M., Ito, H., Sometani, A., Nomoto, H., Furukawa, Y., & Furukawa, S. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35237-1 · Cited by 45
Sphingosine-1-Phosphate Receptors Modulators Decrease Signs of Neuroinflammation and Prevent Parkinson’s Disease Symptoms in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model
Pépin, É., Jalinier, T., Lemieux, G. L., Massicotte, G., & Cyr, M. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00077 · Cited by 43
A dual-hit animal model for age-related parkinsonism
Boger, H. A., Granholm, A., McGinty, J. F., & Middaugh, L. D. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2009.10.013 · Cited by 43
Serum BDNF discriminates Parkinson’s disease patients with depression from without depression and reflect motor severity and gender differences
Huang, Y., Huang, C., Zhang, Q., Wu, W., & Sun, J. (2020) · Journal of Neurology · doi:10.1007/s00415-020-10299-3 · Cited by 43
Use of growth factors for the treatment of Parkinson’s disease
Yasuda, T., & Mochizuki, H. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.55 · Cited by 41
BDNF provides many routes toward STN DBS‐mediated disease modification
Fischer, D. L., & Sortwell, C. E. (2018) · Movement Disorders · doi:10.1002/mds.27535 · Cited by 38
Peripheral BDNF/TrkB protein expression is decreased in Parkinson’s disease but not in Essential tremor
Huang, Y., Huang, C., & Yun, W. (2019) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2019.01.017 · Cited by 38
Differential signaling of glial cell line-derived neurotrophic factor and brain-derived neurotrophic factor in cultured ventral mesencephalic neurons
Feng, L., Wang, C.-Y., Jiang, H., Oho, C., Dugich‐Djordjevic, M. M., Mei, L., & Lu, B. (1999) · Neuroscience · doi:10.1016/s0306-4522(99)00129-3 · Cited by 37
Reelin mRNA expression during embryonic brain development in the turtleEmys orbicularis
Bernier, B., Bar, I., Pieau, C., de Rouvroit, C. L., & Goffinet, A. M. (1999) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19991025)413:3 · Cited by 62
Therapeutic Potential of Repeated Intravenous Transplantation of Human Adipose-Derived Stem Cells in Subchronic MPTP-Induced Parkinson’s Disease Mouse Model
Park, H., & Chang, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218129 · Cited by 34
Association of a variation in the promoter region of the brain-derived neurotrophic factor gene with familial Parkinson's disease
Parsian, A., Sinha, R. R., Racette, B. A., Zhao, J. H., & Perlmutter, J. S. (2004) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2003.12.003 · Cited by 34
Inflammatory Mechanisms in Parkinson’s Disease: From Pathogenesis to Targeted Therapies
Lee, S. Y. H., Yates, N. J., & Tye, S. J. (2021) · The Neuroscientist · doi:10.1177/1073858421992265 · Cited by 34
Challenges and Promises in the Development of Neurotrophic Factor-Based Therapies for Parkinson’s Disease
Rodrigues, T. M., Jerónimo-Santos, A., Outeiro, T. F., Sebastião, A. M., & Diógenes, M. J. (2014) · Drugs & Aging · doi:10.1007/s40266-014-0160-x · Cited by 33
Investigation of tyrosine hydroxylase and BDNF in a low-dose rotenone model of Parkinson's disease
Johnson, M., Lim, Y. P., Senthilkumaran, M., Zhou, X., & Bobrovskaya, L. (2015) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2015.11.002 · Cited by 32
RETRACTED: Do adipose tissue-derived mesenchymal stem cells ameliorate Parkinson’s disease in rat model?
Ahmed, H. H., Salem, A. M. H., Atta, H., Ghazy, M., & Aglan, H. A. (2014) · Human & Experimental Toxicology · doi:10.1177/0960327114524238 · Cited by 31
Retracted
Neurotrophic factors in neurodegenerative disorders: Model of parkinson’s disease
de Yébenes, J. G., & Mena, M. A. (2000) · Neurotoxicity Research · doi:10.1007/bf03033789 · Cited by 31
Neuroscience fundamentals relevant to neuromodulation: Neurobiology of deep brain stimulation in Parkinson's disease
Davidson, B., Milosevic, L., Kondrataviciute, L., Kalia, L. V., & Kalia, S. K. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00348 · Cited by 30
No Association between Brain-Derived Neurotrophic Factor G196A Polymorphism and Clinical Features of Parkinson's Disease
Svetel, M. V., Pekmezovic, T. D., Marković, V., Novaković, I. V., Dobričić, V., Djuric, G., Stefanova, E. D., & Kostić, V. (2013) · European Neurology · doi:10.1159/000352033 · Cited by 30
Brain-Derived Neurotrophic Factor (Val66Met) Polymorphism Does Not Influence Recovery from a Post-Traumatic Vegetative State: A Blinded Retrospective Multi-Centric Study
Bagnato, S., Minafra, L., Bravatà, V., Boccagni, C., Santangelo, A., Castiglione, A., Andriolo, M., Lucca, L. F., TANTI, A. D., Pistarini, C., et al. (2012) · Journal of Neurotrauma · doi:10.1089/neu.2011.2184 · Cited by 30
Neurotrophic Factors and Neurodegenerative Diseases
Ruozi, B., Belletti, D., Bondioli, L., Vita, A. D., Forni, F., Vandelli, M. A., & Tosi, G. (2012) · International review of neurobiology · doi:10.1016/b978-0-12-386986-9.00009-0 · Cited by 29
Strategies for the protection of dopaminergic neurons against neurotoxicity
Gerlach, M., Double, K. L., Youdim, M. B. H., & Riederer, P. (2000) · Neurotoxicity Research · doi:10.1007/bf03033788 · Cited by 29
Electro-Acupuncture Ameliorated MPTP-Induced Parkinsonism in Mice via TrkB Neurotrophic Signaling
Zhao, Y., Luo, D., Ning, Z., Rong, J., & Lao, L. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00496 · Cited by 27
Are TrkB receptor agonists the right tool to fulfill the promises for a therapeutic value of the brain-derived neurotrophic factor?
Zagrebelsky, M., & Körte, M. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.374138 · Cited by 28
Brain-derived neurotrophic factor (BDNF) genetic polymorphism greatly increases risk of leucine-rich repeat kinase 2 (LRRK2) for Parkinson's disease
Liu, J., Zhou, Y., Wang, C., Wang, T., Zheng, Z., & Chan, P. (2011) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2011.09.002 · Cited by 28
Robust changes in expression of brain-derived neurotrophic factor (BDNF) mRNA and protein across the brain do not translate to detectable changes in BDNF levels in CSF or plasma
Lanz, T. A., Bove, S. E., Pilsmaker, C. D., Mariga, A., Drummond, E. M., Cadelina, G. W., Adamowicz, W. O., Swetter, B. J., Carmel, S., Dumin, J. A., et al. (2012) · Biomarkers · doi:10.3109/1354750x.2012.694476 · Cited by 28
Directed Evolution of Brain-Derived Neurotrophic Factor for Improved Folding and Expression in Saccharomyces cerevisiae
Burns, M. L., Malott, T. M., Metcalf, K. J., Hackel, B. J., Chan, J. R., & Shusta, E. V. (2014) · Applied and Environmental Microbiology · doi:10.1128/aem.01466-14 · Cited by 27
Oroxylin A enhances memory consolidation through the brain-derived neurotrophic factor in mice
Kim, D. H., Lee, Y., Lee, H. E., Park, S. J., Jeon, S. J., Jeon, S. J., Cheong, J. H., Shin, C. Y., Son, K. H., & Ryu, J. H. (2014) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2014.09.001 · Cited by 26
MPTP
Royland, J. E., & Langston, J. W. (1998) · Humana Press eBooks · doi:10.1007/978-1-59259-477-1_6 · Cited by 26
Fingolimod (FTY720) is not protective in the subacute MPTP mouse model of Parkinson's disease and does not lead to a sustainable increase of brain‐derived neurotrophic factor
Komnig, D., Dagli, T. C., Habib, P., Zeyen, T., Schulz, J. B., & Falkenburger, B. H. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14575 · Cited by 24
Brain-derived neurotrophic factor expression in the substantia nigra does not change after lesions of dopaminergic neurons
Mocchetti, I., Bachis, A., Nosheny, R. L., & Tanda, G. (2007) · Neurotoxicity Research · doi:10.1007/bf03033922 · Cited by 25
Invited review: Utilizing peripheral nerve regenerative elements to repair damage in the CNS
Seblani, N. E., Welleford, A. S., Quintero, J. E., van Horne, C. G., & Gerhardt, G. A. (2020) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2020.108623 · Cited by 24
Neurotrophic molecules in the treatment of neurodegenerative disease with focus on the retina: status and perspectives
Unsicker, K. (2013) · Cell and Tissue Research · doi:10.1007/s00441-013-1585-y · Cited by 23
Neuropharmacological approach against MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine)-induced mouse model of Parkinson’s disease
Yokoyama, H., Kuroiwa, H., Kasahara, J., & Araki, T. (2011) · Acta Neurobiologiae Experimentalis · doi:10.55782/ane-2011-1847 · Cited by 21
Implantation of autologous peripheral nerve grafts into the substantia nigra of subjects with idiopathic Parkinson's disease treated with bilateral STN DBS: a report of safety and feasibility
van Horne, C. G., Quintero, J. E., Gurwell, J. A., Wagner, R. P., Slevin, J. T., & Gerhardt, G. A. (2016) · Journal of neurosurgery · doi:10.3171/2016.2.jns151988 · Cited by 22

Authors: Tsukahara, T., Takeda, M., Shimohama, S., Ohara, O., & Hashimoto, N.
Affiliations: National Cerebral and Cardiovascular Center (JP)
Kyoto University (JP)
Shionogi (Japan) (JP)
ORCID: Takeda, Makoto
Shimohama, Shun
Ohara, Osamu
Venue: Neurosurgery
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 1995-10-01
Volume: 37
Issue: 4
Pages: 733-741
ISSN: 0148-396X (ISSN-L)
1524-4040
DOI: 10.1227/00006123-199510000-00018
OpenAlex: W1976999555
Cited by: 134
References: 60
Citations by year: 2026: 1 · 2024: 3 · 2023: 6 · 2022: 3 · 2021: 5 · 2020: 8 · 2019: 8 · 2018: 7 · 2016: 9 · 2015: 3 · 2014: 8 · 2013: 6 · 2012: 10
FWCI: 1.83
Type: journal article
Language: en
Open access: closed
Locations: Neurosurgery (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
Keywords: brain-derived neurotrophic factor, Parkinson's disease, MPTP-induced parkinsonism, intrathecal infusion, substantia nigra, neuronal loss, neuroprotection, monkey model
MeSH terms: Animals, Brain, Macaca, Nerve Degeneration, Nerve Growth Factors, Nerve Tissue Proteins, Neurologic Examination, Parkinson Disease, Secondary, Substantia Nigra, Tyrosine 3-Monooxygenase, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Brain-Derived Neurotrophic Factor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effects of Brain-derived Neurotrophic Factor on 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in Monkeys

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks